国际眼科纵览

• 综述 • 上一篇    下一篇

阿托品在近视防控中的应用研究进展

李蔚然 周激波   

  1. 上海交通大学医学院附属第九人民医院眼科 上海市眼眶病眼肿瘤重点实验室, 上海 200011
  • 收稿日期:2015-03-25 出版日期:2019-04-25 发布日期:2019-04-30
  • 通讯作者: 周激波,Email:zhoujibo1000@aliyun.com
  • 基金资助:

    上海交通大学医学院眼视光学专项建设;上海市重点实验室(17DZ2260100)

The research progression of atropine in myopia prevention and control

Li Weiran, Zhou Jibo   

  1. Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine. Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
  • Received:2015-03-25 Online:2019-04-25 Published:2019-04-30
  • Contact: ZHOU Jibo, Email: zhoujibo1000@aliyun.com

摘要:


通信作者:周激波,Email:zhoujibo1000@aliyun.com【摘要】随着近视患病率的逐年上升,寻找有效的近视防控药物变得尤为重要。阿托品是目前公认的能有效控制近视屈光度加深和眼轴长度增长的药物,但副作用限制了其广泛应用。近年来多项研究表明,低浓度、适当频率使用阿托品制剂能有效控制近视发展,并降低其副作用发生率,不影响患者的视觉质量。阿托品制剂联用光学镜,可增加其控制近视发展的效果。(国际眼科纵览,2019, 43: 133-137)

Abstract:

It’s especially important to find an effective medicine for the prevention and control of myopia, since a rising tendency in the past few years. Atropine was known to be able to inhibit myopia progression. However, some side effects prevent atropine from popular clinical work. Recently, researchers find that low\|concentration atropine has much less side effect, compared with high\|concentration atropine, and has more sustained and durable effect without affecting the visual quality of patients. Additionally, combined the optical lenses with atropine eye drops can enhance the preventing effect, compared with using atropine eye drops alone.(Int Rev Ophthalmol, 2019, 43:  133-137)